Center of attention has moved to the newest working thing: management's energy is disproportionately on a small but alre
The model's full reasoning — Q3 2023 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management devotes disproportionate share to one identifiable part minority of results, described as already producing real current business, main driver future. Transcript: Quanterix. Business: Simoa platform, consumables, instruments, Accelerator lab services. Also diagnostics / Alzheimer's blood tests. Revenue Q3: total 31.3M, instruments 3.7M, consumables 16.2M, Accelerator 6.2M. So majority consumables. Management discussion: They talk about transformation, gross margins, cash. Then they talk a lot about Alzheimer's disease, P-tau217, new agreement with J&J, Lucent AD P-tau217 test, CTAD presentations, Lilly, VUMC, etc. They frame future around diagnostics? Need see if this is minority of results. Diagnostics? They have Accelerator lab services, but also LDT? They mention "launched the Lucent AD P-tau217 blood based biomarker test" combining Quanterix and J&J antibodies. This is a product/test. Is it currently producing revenue? They don't explicitly say revenue from this test. They talk about "we signed a new agreement with Johnson & Johnson Innovative Medicines and launched the Lucent AD P-tau217 blood based biomarker test" - launched, but no revenue figures. They talk about "our LDT and our kit sales" in response to deal economics. They say "Quanterix expects majority of the economics to come from our LDT and our kit sales and what we're doing in the market and trying to get 217 into a lot of folks' hands." So it's a product line. Is it minority? Yes, likely diagnostics is small vs research consumables. But is it described as already producing real current business? They mention "launched" and "we are working with VUMC and ABBS on a clinical trial" etc. They mention "we signed a new agreement" - that's a deal, not necessarily revenue. They mention "our P-tau217 test achieved sensitivity..." That's performance. They don't give revenue or orders for this test. They mention "we are in a strong position to capitalize on these opportunities from supporting clinical trials to use in diagnosis." That sounds future. But they also say "we launched the Lucent AD P-tau217 blood based biomarker test" - launched means available, but not necessarily current revenue. Need see if management treats it as main driver.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| APAM | Artisan Partners Asset Management Inc. | Q3 2023 | 2023-11-01 | C+ |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| PKX | POSCO Holdings Inc. | Q3 2022 | 2022-10-24 | D |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
YMM · Q2 2022 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clear, extended spotlight to the commission/online transaction service (20%+ of revenue, minority share). They repeatedly highlight its strong performance, dynamic adjustments, user retention metrics, and role in driving monetization and future growth, framing it as a key driver for the company's trajectory while 347.8 million in commissions is already generating real revenue now. Other areas like overall GTV, fulfillment rates, and user MAUs receive routine coverage, but the commission piece gets the richest, most conviction-driven discussion.
PUMP · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its prepared remarks and Q&A to the FORCE electric fleet offering (a new technology/service line). They describe it as minority today (only two fleets operating out of 14-15 active, with plans for three and four more), yet repeatedly highlight its real 2023 performance (on contract, strong results, efficient performance, customer satisfaction, diesel displacement), its unique positioning, and its role as the core driver of the company's future trajectory through fleet transition and industrialization.
NICE · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its energy, enthusiasm, and detail to AI (Enlighten AI, Copilot, Autopilot) as the catalyst driving growth across CXone, digital engagement, platformization, and new solutions. This is framed as the overarching theme that will shape the 2024 trajectory and beyond. AI is described as already producing real, current business activity: 375% increase in Enlighten bookings in Q4, multiple seven-digit ACV deals won with AI features, and accelerating adoption among customers and prospects.